Tigatuzumab

Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5) . Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer[1].

Product Specifications

CAS Number

[918127-53-4]

Product Name Alternative

CS-1008; Anti-Human TRAIL-R2 Recombinant Antibody

UNSPSC

12352203

Target

Apoptosis

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tigatuzumab.html

Purity

99.90

Solubility

10 mM in DMSO

Smiles

[Tigatuzumab]

Molecular Weight

(144.64 kDa)

References & Citations

[1]Yamamoto J, et al. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model. Cancer Lett. 2020 Nov 1;492:174-184.